Additionally, the knowledge of CYP2D6 polymorphism in SLE may help establish a recommendation for considering genetic markers in optimizing care and therapy for lupus patients, particularly in the case of specific organ involvement. This evidence concerns the gene CYP2D6 and systemic lupus erythematosus.